Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Ponatinib |
Trade Name | Iclusig |
Synonyms | AP24534 |
Drug Descriptions |
Iclusig (ponatinib) inhibits the Bcr-Abl fusion, and other tyrosine kinases, such as RET, DDR, VEGFR, FGFR, KIT, and FLT3 (PMID: 23526464, PMID: 25284748, PMID: 19878872). Iclusig (ponatinib) is FDA approved for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL) as well as ABL1 T315I CML and ABL1 T315I Ph positive ALL (FDA.gov). |
DrugClasses | ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 29 DDR1 Inhibitor 8 DDR2 inhibitor 7 FGFR Inhibitor (Pan) 24 FLT3 Inhibitor 61 KIT Inhibitor 55 PDGFR-alpha Inhibitor 10 RET Inhibitor 48 SRC Inhibitor 31 VEGFR Inhibitor (Pan) 33 |
CAS Registry Number | 943319-70-8 |
NCIT ID | C95777 |